Incyte, Syndax Team Up On Chronic GVHD, But Some Uncertainties Remain

Data Still Early For Drug In $600m Deal

The deal could nevertheless give Incyte a competitive edge, especially with combination potential between its JAK inhibitors and Syndax’s axatilimab.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
Syndax and Incyte announced a deal worth more than $600m to develop drugs for chronic GVHD • Source: Shutterstock

Incyte Corporation is looking to broaden its presence in the market for chronic graft-versus-host disease (cGVHD) therapies with a global deal to develop and commercialize Syndax Pharmaceuticals, Inc.’s monoclonal antibody for the drug, just days after Incyte’s flagship drug received US Food and Drug Administration approval for the same disease.

However, while Syndax’s drug axatilimab has shown a high response rate in heavily pretreated cGVHD patients, the company has only...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business